Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-13

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Protein Expression in Samples From Young Patients With Rhabdomyosarcoma

NCT01426945

Sarcoma

COMPLETED

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

NCT03265496

Nsclc

TERMINATED NA

Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma

NCT01609803

Alveolar Childhood Rhabdomyosarcoma Embryonal Childhood Rhabdomyosarcoma Previously Treated Childhood Rhabdomyosarcoma +2 more

COMPLETED

Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma

NCT01365962

Sarcoma

COMPLETED

Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma

NCT01585376

Sarcoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-interventional, monocentric, retrospective cohort study aimed at developing a spatial proteomics analysis method for small tumor samples (FFPE) to precisely characterize proteins at the tissue level in rhabdomyosarcoma (RMS). Using mass spectrometry, the study will identify molecular signatures associated with different tumor regions, histological subtypes, patient survival, and treatment resistance. The goal is to identify potential protein biomarkers and therapeutic targets. Data from clinical samples will be analyzed to find biomarkers correlated with survival and resistance to treatment. No patient intervention is required, as the study uses pre-existing biological samples and clinical data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhabdomyosarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

None AHT

This study does not involve any interventions. It analyzes pre-existing biological samples (FFPE tumor tissue) and clinical data from patients with rhabdomyosarcoma.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 0 and 25 years at the time of initial diagnosis
* Diagnosis of rhabdomyosarcoma confirmed histologically
* Care at the Oscar Lambret Center between January 2005 and November 2024
* No objection to the re-use of data and biological samples collected as part of care for research activities.

Exclusion Criteria

* Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret;
* Patient under guardianship or trusteeship.

Minimum Eligible Age

0 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No